After hours: March 10 at 7:59:36 PM EDT Loading Chart for ABBV ...

AbbVie (ABBV) and Gubra announced a license agreement to develop GUB014295, a long-acting amylin analog for the treatment of obesity. Under the terms of the agreement, AbbVie will lead development ...

AbbVie and Anima Biotech have announced that they are collaborating in a deal worth up to over $580 million to discover and develop drugs that modulate mRNA biology for three targets in cancer and ...

The partnership will combine the oncology expertise of AbbVie and Xilio’s technology to develop the immunotherapies. Credit: © AbbVie Inc. All rights reserved ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...

NORTH CHICAGO, Ill., Feb. 13, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share. The cash dividend is payable May ...

February 20. Holiday concept.... National Love Your Pet Day. February 20. Holiday concept. Template for background, banner, card, poster with text inscription. Vector EPS10 illustration Pet ...

AbbVie is joining the industry’s rush to develop new obesity medicines, announcing Monday a deal with Denmark-based Gubra to license a drug that could compete with experimental therapies being ...

Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. This time, the pharma is paying Xilio Therapeutics $52 million upfront to work on antibody-based ...

Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global ...